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iology of acute coronary syndrome (ACS). The aim of the study was the evaluation of inﬂammation
(white blood cells count/WBC, C-reactive protein/CRP, interleukin-6/IL-6) and platelet (platelet
count/PLT, mean platelet volume/MPV, large platelet/LPLT, beta-thromboglobulin/b-TG)
biomarkers in the groups of ACS patients depending on the severity of signs and symptoms and
compared to controls without coronary artery disease.
Materials and methods: The study group included 93 patients categorized into 3 subgroups
depending on the severity of signs and symptoms of ACS. PLT, MPV, LPLT, and WBC were deter-
mined on hematological analyzer, IL-6 and b-TG were measured using the ELISA method.
Results: In the whole group of ACS patients WBC, CRP, IL-6, MPV, and b-TG were signiﬁ-
cantly higher as compared to controls. Analyzing the inﬂammation and platelet biomarkers depend-
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Biological Sciences (2016), http://dx.doi.org/differences for above-mentioned parameters were also found. There were no signiﬁcant differences
between the advancement of coronary artery changes and inﬂammation as well as platelet param-
eters, except for CRP concentrations. The AUCs for all inﬂammation parameters tested were sim-
ilar, however the highest AUCs showed WBC and CRP. Among platelet parameters the highest
AUC revealed b-TG.
Conclusion: Markers of inﬂammation and platelet activation may be associated to myocardial
ischemia and myocardial injury. WBC, CRP and IL-6 as inﬂammation parameters and MPV
and b-TG as platelet biomarkers may be useful indicators of the presence of coronary artery dis-
ease.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute coronary syndrome (ACS), the initial presentation of
coronary artery disease, is the umbrella term utilized for the
clinical signs and symptoms of myocardial ischemia (Go
et al., 2014; Heeschen et al., 2005). Depending on the
sensitivity of signs and symptoms ACS may be classiﬁed as
non-ST-segment elevation myocardial infarction (NSTEMI),
ST-segment elevation myocardial infarction (STEMI), or
unstable angina (UA) (Heeschen et al., 2005). ACS can lead
to adverse cardiovascular events such as sudden cardiac death
(Wang et al., 2014). Therefore strategies concerning the pre-
vention of acute coronary events belong to the most important
public health goals and identifying subjects at increased risk of
ACS, who may beneﬁt from preventative procedures, nowa-
days is a major challenge (Arbab-Zadeh et al., 2012).
Atherosclerosis is a chronic inﬂammatory arterial disease
developing over decades, characterized by an impaired lipid
metabolism and imbalanced immune response, which lead to
the subendothelial lipoprotein retention and activation of
endothelial cells with continuous migration of leukocytes and
smooth muscle cells to the inﬂamed intima. Acute occlusive
atherothrombotic complications, such as myocardial infarc-
tions (MI) and strokes, result from the formation of vulnerable
atherosclerotic plaque (Hristov and Weber, 2015).
Acute myocardial infarction is a typical sterile inﬂamma-
tion, in which hyperglycemia, increased concentrations of
inﬂammatory cytokines, platelet activation, as well as leukocy-
tosis are recognized. Macrophages and mast cells, which are
deeply involved in atherosclerotic plaque formation, generate
pro-inﬂammatory cytokines, such as IL-1, IL-6, TNF-a, and
IFN-p. Moreover mast cells, also release vasoactive and angio-
genic compounds, pro-inﬂammatory mediators, such as
arachidonic acid metabolites, histamine, platelet activating fac-
tor (PAF), and proteolytic enzymes, via the accumulation in
the arterial intima and adventitia during atherosclerotic plaque
progression (Spinas et al., 2014).
Repair of the vascular damage and preservation of the
patency of narrow capillaries is a complex mechanism, in
which platelets are key regulatory players. In atherosclerosis
platelets contribute to the endothelial dysfunction as well as
the rupture of the vulnerable plaque (Nording et al., 2015).
The interaction of platelets with endothelial cells leads to an
excessive platelet activation, which results in shorter half-life
and increased platelet turnover. It may inﬂuence the platelet
count (PLT), mean platelet volume (MPV) as well as the per-
centage of large platelets (LPLT) (Pal et al., 2014), which areJ. et al., The utility of inflammation and
10.1016/j.sjbs.2016.10.015deﬁned as platelets above 12 fL. Speciﬁc proteins are released
during platelet activation. The ﬁrst platelet-speciﬁc protein,
isolated in 1975 and released during platelet aggregation, is
beta-thromboglobulin (b-TG) (Borsey et al., 1980; Kaplan
and Owen, 1981). Moreover, within the atherosclerotic plaque
platelets could remain activated for a long time providing for
proinﬂammatory cytokines production, e.g. IL-6 (Nording
et al., 2015). So far many biomarkers of inﬂammation have
been utilized as a markers of ACS. Most of the studies con-
cerned C-reactive protein, ﬁbrinogen, and IL-6. These inﬂam-
matory biomarkers have high sensitivity and thus are indicated
as a good prognostic and evolution-monitoring markers
(Gilardi et al., 2014).
Elevated concentrations of cardiac troponins as a speciﬁc
and sensitive biomarkers of myocardial-cell necrosis are noted
in about 1/3 of ACS cases (Heeschen et al., 2003, 2005). How-
ever, cardiac troponins are not actively engaged in the patho-
physiology of ACS (Heeschen et al., 2003). It is suggested that
the main role in the development of ACS play both the inﬂam-
matory as well as thrombotic processes. According to Hansson
G.K. ‘‘most cases of infarction are due to the formation of an
occluding thrombus on the surface of the plaque” (Hansson,
2005). Inﬂammation plays the pivotal role in platelet activa-
tion and thrombotic complications in ACS (Tanindi et al.,
2011; Zhang et al., 2007). In respect to the above mentioned
issues, markers of inﬂammation together with platelet activa-
tion parameters may be useful indicators of disease activity,
by the time myocardial-cell necrosis occurs. Therefore the
aim of the current study was the evaluation of inﬂammation
markers (white blood cells count/WBC, C-reactive protein/
CRP, interleukin-6/IL-6) concentrations, chosen platelet mor-
phological parameters (platelet count/PLT, mean platelet vol-
ume/MPV, large platelet/LPLT) as well as beta-
thromboglobulin/b-TG activity in the group of ACS patients
(STEMI, NSTEMI, and UA) as compared to the control
group without coronary artery disease. In the next step of
the study we try to establish the diagnostic signiﬁcance of
parameters tested.
2. Material and methods
2.1. Study group and control group
The study group included 93 patients (34F/59 M, mean age 63,
ranged 29–93 years) with ACS, diagnosed and hospitalized at
the Department of Cardiology Intensive Care with the Hemo-
dynamic Unit of the Provincial Hospital in Bialystok. Table 1platelet biomarkers in patients with acute coronary syndromes. Saudi Journal of
Table 1 Clinical characteristics of the total group of ACS patients and depending on the severity of signs and symptoms.
ACS STEMI NSTEMI UA P-value
N= 93 N= 33 N= 30 N= 30 STEMI vs. NSTEMI vs. UA
Age (years) 63 (29–93) 62 (35–87) 62 (29–85) 66 (48–93)
Sex: F/M 34/59 13/20 11/19 11/19
Systolic BP [mmHg] 140 (120–160) 130 (116–160) 150 (130–170) 130 (120–160) NS
Diastolic BP [mmHg] 80 (70–90) 80 (70–90) 87 (80–96) 80 (75–85) NS
TCH [mg/dL] 183 (159–211) 179 (162–205) 194 (157–224) 183 (156–212) NS
LDL [mg/dL] 113 (80–135) 108 (89–134) 120 (83–139) 99 (73–131) NS
HDL [mg/dL] 49 (41–59) 50 (42–57) 43 (38–56) 49 (43–61) NS
TG [mg/dL] 105 (68–148) 99 (57–131) 106 (76–148) 111 (71–198) NS
Glucose [mg/dL] 102 (93–112) 104 (94–129) 105 (101–126) 93 (86–101) 0.0012*
Sodium [mmol/L] 139 (137–140) 138 (135–140) 139 (136–140) 140 (139–141) 0.0034*
Potassium [mmol/L] 4.26 (3.96–4.50) 4.25 (3.88–4.42) 4.25 (3.96–4.47) 4.28 (4.13–4.50) NS
Creatinine [mg/dL] 0.88 (0.71–0.99) 0.88 (0.71–1.01) 0.82 (0.71–0.95) 0.88 (0.78–0.97) NS
eGFR [mL/min/1.73m2] 91 (76–104) 92 (77–108) 93 (81–104) 88 (70–101) NS
Urea [mg/dL] 38 (31–43) 40 (33–43) 33 (26–40) 39 (31–47) NS
AST [U/I] 29 (20–79) 53 (28–116) 44 (19–79) 20 (16–22) 0.0013*
ALT [U/I] 22 (15–35) 27 (20–37) 25 (14–41) 20 (13–26) NS
RBC [x106/lL] 4.61 (4.26–4.95) 4.53 (4.10–5.11) 4.69 (4.46–5.93) 4.56 (4.32–4.95) NS
HGB [g/dL] 14.2 (13.2–15.0) 14.0 (12.0–14.9) 14.2 (13.5–15.3) 14.3 (13.1–15.4) NS
HCT [%] 41.4 (38.1–43.7) 40.8 (36.2–43.8) 41.0 (39.3–43.5) 42.2 (38.0–44.2) NS
Troponin I [ng/mL] 9.28 (0.22–25.00) 25.00 (25.00–25.00) 9.28 (6.06–23.4) 0.10 (0.10–0.14) 0.0000*
1-vessel disease [N] 40 (43%) 17 (43%) 11 (27%) 12 (30%)
2-vessels disease [N] 24 (26%) 10 (42%) 9 (37.5%) 5 (20.5%)
3-vessels disease [N] 19 (21%) 5 (26%) 8 (42%) 6 (32%)
ACS – acute coronary syndrome, F – female, M – male, BP – blood pressure, TCH – total cholesterol, LDL – low-density lipoprotein
cholesterol, HDL – high-density lipoprotein cholesterol, TG – triglycerides, eGFR – estimate glomerular ﬁltration rate, AST – aspartate
transaminase, ALT – alanine transaminase, RBC – red blood cell count, HGB - hemoglobin, HCT – hematocrit, STEMI – ST-segment elevation
myocardial infarction, NSTEMI – non-ST-segment elevation myocardial infarction, UA – unstable angina, NS – not statistically signiﬁcant.
Conversion factors to SI units are as follows: for glucose – 0.0555, for TCH – 0.0259, for LDL – 0.0259, for HDL – 0.0259, for TG - 0.0113, for
creatinine – 88.4, for urea – 59.48, for RBC – 1.0, for HGB – 10.0, for HCT – 0.01.
* The analysis of differences between the ACS subgroups showed that signiﬁcant variations were found, therefore in the next step the post hoc
Dwass-Steele-Critchlow-Fligner test was conducted. Obtained P-value results are as follows: Glucose: STEMI vs. NSTEMI= NS, STEMI vs.
UA= 0.0321, NSTEMI vs. UA= 0.0011; Sodium: STEMI vs. NSTEMI= NS, STEMI vs. UA= 0.0030, NSTEMI vs.UA=NS; AST:
STEMI vs. NSTEMI = NS, STEMI vs. UA= 0.0008, NSTEMI vs. UA=NS.
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teria of ACS diagnosis included the detection of rise and/or fall
of cardiac troponin I (cTnI) with at least one value above 99th
percentile URL, and at least one of the following: clinical
symptoms of ischemia, new or presumed new signiﬁcant ST-
segment-T wave changes or new Left Bundle Branch Block
(LBBB), development of pathological Q waves, imaging evi-
dence of new loss of viable myocardium, a new regional wall
motion abnormality. The exclusion criteria were: active inﬂam-
mation, cancer, chronic circulatory insufﬁciency, severe renal
failure, acute coronary syndrome in medical history, antiplate-
let drugs (acetylsalicylic acid, clopidogrel, ticagrelor), and anti-
coagulant treatment (acenocoumarol, warfarin, dabigatran,
rivaroxaban).
The study group was divided according to the clinical and
biochemical criteria of the European Society of Cardiology
into three sub-groups:
1. patients with STEMI: 33 patients (13 F/20 M, mean age 62,
ranged 35–87 years)
2. patients with NSTEMI: 30 patients (11F/19 M, mean age
62, ranged 29–85 years)
3. patients with UA: 30 patients (11F/19 M, mean age 66, ran-
ged 48–93 years)Please cite this article in press as: Kamin´ska, J. et al., The utility of inflammation and
Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.10.015The control group included 30 healthy volunteers
(15F/15 M, mean age 66, ranged 45–77 years), undergoing
their periodical checkups at the Occupational Health Clinic
of the Medical University Hospital in Bialystok. Their medical
history did not reveal any cardiovascular problems, hyperten-
sion, neoplasia or diabetes. Moreover, routinely performed
echocardiogram (ECG) was normal and the concentration of
cTnI was within allowed range.
The study protocol was accepted by the Local Bioethics
Committee (R-I-002/122/2013). All subjects included to the
study gave their written informed consent.
2.2. Samples handling and storage
Blood samples from all subjects included to the study were
drawn immediately after the diagnosis of ACS. Samples col-
lected into EDTA-K2 tubes were analyzed within 2 h of
venipuncture. Tubes with the blood collected without antico-
agulant were allowed to clot for 30 min before centrifugation
(15 min at 1000g); obtained serum was stored at 75 C until
further analysis. Blood collected into tubes containing CTAD
(citrate, theophylline, adenosine and dipyridamole) anticoagu-
lant was allowed in the ice bath for at last 15 min, and after
that tubes were centrifuged (20 min at 2500g, at 2–8 C)
within one hour from the blood collection. After the ﬁrst cen-platelet biomarkers in patients with acute coronary syndromes. Saudi Journal of
Table 2 Inﬂammation and platelet biomarkers in the total
group of ACS patients (STEMI, NSTEMI, and UA) compared
to the controls. Results are presented as medians and
interquartile ranges.
ACS C P
N= 93 N= 30
WBC [x103/lL] 8.20 (6.70–10.1) 6.31 (5.38–7.35) 0.0000
CRP [mg/L] 2.1 (0.9–4.2) 0.75 (0.5–1.1) 0.0000
IL-6 [pg/mL] 12.0 (5.5–17.6) 7.6 (6.9–8.1) 0.0009
PLT [x103/lL] 217 (179–243) 233 (207–250) NS
MPV [fL] 11.0 (10.1–11.3) 9.4 (9.2–9.8) 0.0000
b-TG [IU/mL] 81 (53–101) 29 (23–33) 0.0000
WBC – white blood cells count, CRP – C-reactive protein, IL-6 –
interleukin-6, PLT – platelet count, MPV – mean platelet volume,
L-PLT – large platelet, b-TG – b-thromboglobulin, STEMI – ST-
segment elevation myocardial infarction, NSTEMI – non-ST-seg-
ment elevation myocardial infarction, UA – unstable angina.
Conversion factors to SI units are as follows: for WBC – 1.0, for
PLT – 1.0.
4 J. Kamin´ska et al.trifugation one-third volume of the obtained plasma was
removed from the middle region of the supernatant and cen-
trifuged a second time (20 min at 2500g, at 2–8 C). Once
again one-third volume of the obtained plasma was removed
from the middle region of the supernatant, aliquoted into sev-
eral portions of 200 lL, and frozen at 20 C until assayed.
2.3. The evaluation of inflammation and platelet biomarkers
The platelet count (PLT), mean platelet volume (MPV), the
percentage of large platelet (LPLT), and white blood cells
count (WBC) were determined in the whole blood collected
into EDTA-K2 tubes with the use of SYSMEX XT 4000i
hematological analyzer (Sysmex America, Mundelein, IL,
USA) according to the manufacturer’s instruction.
The C-reactive protein (CRP) and cTnI concentrations in
the serum were determined with use of enzymatic-
spectrophotometric method on the Cobas 6000 analyzer
(Roche Diagnostics, Indianapolis, USA).
Serum levels of IL-6 were measured using ELISA Quan-
tikine Human IL-6 Immunoassay kit (Catalog number:
D60504; R&D Systems Europe Ltd., Abingdon, England)
according the manufacturer’s instruction. Samples were not
diluted before analysis. The manufacturer of assay kits referred
to the intra-assay coefﬁcient of variation (CV%) as 4.2% at
IL-6 mean concentration of 16.8 pg/mL, SD = 0.7 pg/mL.
Plasma b-TG activity was measured using commercially
available ELISAs (Catalog number: 00950; ASSERACHROM
 b-TG, Diagnostica Stago S.A.S., France) according the
manufacturer’s instruction. Samples were not diluted before
analysis. The manufacturer of assay kits referred to the
intra-assay coefﬁcient of variation (CV%) as 6.6% at b-TG
mean activity of 28.7 IU/mL, SD = 1.9 IU/mL.
2.4. Coronary angiography
Coronary angiography and angioplasty were performed in the
course of ACS. During coronary angiography 6F catheter was
applied. Percutaneous coronary interventions (PCIs) were rou-
tinely performed via right radial artery. Standard angiographic
projections were used. A signiﬁcant coronary lesion was
deﬁned as lumen stenosis of more than 70%. According to
the coronary angiography results patients were distinguished
into one-, two-, and three-vessel disease subgroups as well as
patients without angiographically signiﬁcant coronary lesion.
2.5. Statistical analysis
The obtained results were statistically analyzed with the use of
the STATISTICA 12.0 PL software (StatSoft Inc., Tulsa,
USA). The concentrations of protein tested did not follow
the normal distribution in the preliminary statistical analysis
(X2-test), thus nonparametric statistical analysis was
employed. The Mann–Whitney test and Kołmogorov–Smir
nov test were used in order to compare two independent sam-
ples and ANOVA rank Kruskal–Wallis test was used for the
comparison of three samples. The post hoc Dwass–Steele–Crit
chlow–Fligner test was conducted to assess which groups were
different, if signiﬁcant differences were found. The values for
each given measured variable are given in medians and
interquartile ranges. Differences were considered statisticallyPlease cite this article in press as: Kamin´ska, J. et al., The utility of inflammation and
Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.10.015signiﬁcant for P< 0.05. Correlation coefﬁcients were obtained
by applying Spearman’s rank method.
The relation between the sensitivity and speciﬁcity was
obtained using a receiver operator characteristic (ROC) curve.
The ROC curve is a line graph that plots the probability of
true positive results – or the sensitivity of the test – against
the probability of false positive results for a range of different
cut-off points. ROC curves to calculate the areas under the
ROC curves (AUCs), positive predictive values (PPV), nega-
tive predictive values (NPV), diagnostic accuracy (ACC), as
well as standard errors (SE) were generated with the use of
the STATISTICA 12.0 PL software (StatSoft Inc., Tulsa,
USA).
3. Results
3.1. Inflammation biomarkers
In the total group of ACS patients median (Me) WBC, CRP as
well as IL-6 were signiﬁcantly higher as compared to controls
(Table 2).
Analyzing the inﬂammation biomarkers depending on the
sensitivity of signs and symptoms in comparison to control
group studies revealed that statistically signiﬁcant differences
were found for WBC, CRP and IL-6 (except between UA sub-
group vs. controls for IL-6) (Table 3).
The analysis of differences between the ACS subgroups
showed that signiﬁcant variations were found for CRP and
IL-6 concentrations (Table 4), therefore in the next step the
post hoc Dwass–Steele–Critchlow–Fligner test was conducted.
Studies revealed that among the ACS subgroups statistically
signiﬁcant differences were found between STEMI vs. UA sub-
group (P= 0.0230) for CRP concentrations and between
STEMI vs. UA subgroup (P= 0.0000) as well as between
NSTEMI vs. UA subgroup (P= 0.0000) for IL-6 concentra-
tions (Table 4). Statistically signiﬁcant differences were also
found for CRP and IL-6 concentrations in the STEMI
+ NSTEMI subgroup as compared to the UA subjects
(Table 5).platelet biomarkers in patients with acute coronary syndromes. Saudi Journal of
Table 3 Inﬂammation and platelet biomarkers in the subgroups of ACS patients depending on the sensitivity of signs and symptoms
(STEMI, NSTEMI, and UA) compared to controls. Results are presented as medians and interquartile ranges.
STEMI
N= 33
NSTEMI
N= 30
UA
N= 30
C
N= 30
P
STEMI vs. C
NSTEMI vs. C
UA vs. C
WBC [x103/lL] 8.70 (7.50–10.00) 8.05 (7.50–10.00) 7.65 (5.80–9.50) 6.31 (5.38–7.35) 0.0000
0.0000
0.0030
CRP [mg/L] 3.5 (1.4–5.0) 2.0 (0.9–3.9) 1.3 (0.9–2.9) 0.75 (0.5–1.1) 0.0000
0.0002
0.0018
IL-6 [pg/mL] 12.8 (9.9–17.4) 18.8 (12.2–24.1) 5.4 (2.2–11.0) 7.6 (6.9–8.1) 0.0001
0.0000
NS
PLT [x103/lL] 222 (188–273) 206 (168–254) 210 (175–223) 233 (207–250) NS
NS
0.0062
MPV [fL] 10.9 (10.0–11.5) 10.9 (10.2–11.2) 11.1 (10.4–11.3) 9.4 (9.2–9.8) 0.000
0.000
0.000
b-TG [IU/mL] 69 (53–118) 71 (53–128) 70 (53–95) 29 (23–33) 0.000
0.000
0.000
WBC – white blood cells count, CRP – C-reactive protein, IL-6 – interleukin-6, PLT – platelet count, MPV – mean platelet volume, L-PLT –
large platelet, b-TG – b-thromboglobulin, STEMI – ST-segment elevation myocardial infarction, NSTEMI – non-ST-segment elevation
myocardial infarction, UA – unstable angina.
Conversion factors to SI units are as follows: for WBC – 1.0, for PLT – 1.0.
Table 4 Inﬂammation and platelet biomarkers in the subgroups of ACS patients depending on the sensitivity of signs and symptoms
(STEMI, NSTEMI, and UA). Results are presented as medians and interquartile ranges.
STEMI
N= 33
NSTEMI
N= 30
UA
N= 30
P-value
WBC [x103/lL] 8.70 (7.50–10.00) 8.05 (7.50–10.00) 7.65 (5.80–9.50) NS
CRP [mg/L] 3.5 (1.4–5.0) 2.0 (0.9–3.9) 1.3 (0.9–2.9) 0.0251*
IL-6 [pg/mL] 12.8 (9.9–17.4) 18.8 (12.2–24.1) 5.4 (2.2–11.0) 0.0000*
PLT [x103/lL] 222 (188–273) 206 (168–254) 210 (175–223) NS
MPV [fL] 10.9 (10.0–11.5) 10.9 (10.2–11.2) 11.1 (10.4–11.3) NS
LPLT [%] 30.9 (25.6–34.2) 31.4 (28.0–35.1) 32.4 (27.9–34.0) NS
b-TG [IU/mL] 69 (53–118) 71 (53–128) 70 (53–95) NS
WBC – white blood cells count, CRP – C-reactive protein, IL-6 – interleukin-6, PLT – platelet count, MPV – mean platelet volume, L-PLT –
large platelet, b-TG – b-thromboglobulin, STEMI – ST-segment elevation myocardial infarction, NSTEMI – non-ST-segment elevation
myocardial infarction, UA – unstable angina.
Conversion factors to SI units are as follows: for WBC – 1.0, for PLT – 1.0
* The analysis of differences between the ACS subgroups showed that signiﬁcant variations were found, therefore in the next step the post hoc
Dwass-Steele-Critchlow-Fligner test was conducted. Obtained P-value results are as follows: CRP: STEMI vs. NSTEMI = NS, STEMI vs.
UA= 0.0230, NSTEMI vs. UA=NS; IL-6: STEMI vs. NSTEMI = NS, STEMI vs. UA= 0.0000, NSTEMI vs. UA= 0.0000.
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In the total group of ACS patients Me MPV and b-TG activity
were signiﬁcantly higher as compared to controls (Table 2).
Analyzing the platelet biomarkers depending on the sensi-
tivity of signs and symptoms as compared to control group
studies revealed that statistically signiﬁcant differences were
found for MPV and b-TG. Differences regarding PLT were
found only in case of UA subgroup vs. control group (Table 3).
The analysis of differences between the ACS subgroups did
not reveal any statistically signiﬁcant variations (Table 4). AlsoPlease cite this article in press as: Kamin´ska, J. et al., The utility of inflammation and
Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.10.015analyzing the STEMI + NSTEMI subgroup as compared to
the UA subjects studies did not show any differences (Table 5).
3.3. Association between inflammation and platelet parameters
and angiographic extent of the coronary artery disease in the
total group of ACS patients
There were no signiﬁcant differences between the advancement
of coronary artery changes and inﬂammation as well as plate-
let parameters, except for CRP concentrations (Table 6). How-
ever to post hoc test conducted for CRP revealed that proteinplatelet biomarkers in patients with acute coronary syndromes. Saudi Journal of
Table 5 Inﬂammation and platelet biomarkers in the group of
STEMI + NSTEMI subjects as compared to UA subjects.
Results are presented as medians and interquartile ranges.
STEMI + NSTEMI
N= 63
UA
N= 30
P
WBC [x103/lL] 8.40 (7.30–10.20) 7.65 (5.80–9.50) NS
CRP [mg/L] 2.8 (0.9–4.6) 1.3 (0.9–2.9) 0.0357
IL-6 [pg/mL] 12.2 (4.1–18.8) 5.4 (2.2–11.0) 0.0000
PLT [x103/lL] 212 (183–257) 210 (175–223) NS
MPV [fL] 10.9 (10.1–11.3) 11.1 (10.4–11.3) NS
LPLT [%] 31.3 (2.57–35.1) 32.4 (27.9–34.0) NS
b-TG [IU/mL] 69 (53–123) 70 (53–95) NS
WBC – white blood cells count, CRP – C-reactive protein, IL-6 –
interleukin-6, PLT – platelet count, MPV – mean platelet volume,
L-PLT – large platelet, b-TG – b-thromboglobulin, STEMI
– ST-segment elevation myocardial infarction, NSTEMI – non-ST-
segment elevation myocardial infarction, UA – unstable angina.
Conversion factors to SI units are as follows: for WBC – 1.0, for
PLT – 1.0.
6 J. Kamin´ska et al.tested was statistically lower only in the group of ACS patients
with 1-vessel coronary artery disease as compared to subjects
with 2-vessel coronary artery disease (P= 0.0292).
3.4. Diagnostic usefulness of inflammation and platelet
biomarkers
The percentage of elevated results (diagnostic sensitivity) were
higher for WBC (98%) and CRP (96%) than those of IL-6
(67%). However the highest speciﬁcity revealed IL-6 (90%).
IL-6 also showed the highest PPV (94%) as well as diagnostic
accuracy (76%). The highest NPV was found for WBC (67%)
(Table 6). Among inﬂammation biomarkers the highest areas
under the ROC curves (AUCs) were found for WBC
(AUC= 0.787) and for CRP (AUC= 0.798). The percentage
of elevated results were higher for MPV (93%) than those of b-
TG (89%); however the highest speciﬁcity revealed b-TG
(93%). b-TG also showed the highest PPV (90%), NPV
(97%), and diagnostic accuracy (90%) (Table 7). Among pla-
telet biomarkers the highest AUC was revealed for b-TG
(AUC= 0.961) (Table 7).Table 6 Association between inﬂammation and platelet parameters
group of ACS patients.
No changes in coronary arteries
N= 10
1-vessel dis
N= 40
WBC [x103/lL] 7.75 (6.50–8.60) 8.75 (7.00–
CRP [mg/L] 3.0 (1.6–3.9) 2.3 (0.8–2.8
IL-6 [pg/mL] 11.1 (10.1–12.0) 13.7 (5.0–1
PLT [x103/lL] 231 (198–286) 216 (173–2
MPV [fL] 11.1 (10.9–11.5) 10.9 (10.3–
LPLT [%] 33.2 (30.1–37.0) 31.3 (27.6–
b-TG [IU/mL] 58 (36–80) 89 (53–120
ACS – acute coronary syndrome, WBC – white blood cells count, CRP –
mean platelet volume, L-PLT – large platelet, b-TG – b-thromboglobuli
Conversion factors to SI units are as follows: for WBC – 1.0, for PLT – 1
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The aim of the current study was the evaluation of inﬂamma-
tion (WBC, CRP, IL-6) as well as platelet (PLT, MPV, LPLT,
b-TG) biomarkers in the group of ACS patients (UA, STEMI,
and NSTEMI) compared to the control group without coro-
nary artery disease. According to the best of our knowledge
studies evaluating in conjunction both groups of biomarkers
engaged in the pathophysiology of CAD are limited. More-
over, which should be emphasized, this is the ﬁrst study assess-
ing the activity of b-TG in STEMI, NSTEMI, and UA
subjects.
Studies revealed that patients with CAD have increased
concentrations of proinﬂammatory biomarkers, such as
TNF-a, CRP, and IL-6 (Lindahl et al., 2000; Sukhija et al.,
2007; Williams et al., 2014; Zhang et al., 2007). Our study also
showed statistically signiﬁcant elevation in chosen inﬂamma-
tion biomarkers (WBC, CRP, IL-6) in the whole group of
ACS patients in comparison to controls. Analyzing the inﬂam-
mation biomarkers depending on the sensitivity of signs and
symptoms as compared to control group studies revealed, that
statistically signiﬁcant differences were also found for all above
parameters tested. The analysis of differences between the ACS
subgroups showed that signiﬁcant variations were found for
CRP and IL-6 concentrations, but not for WBC.
Synthesis of CRP is regulated by IL-6, thus the strong cor-
relation between these biomarkers was reported (Lai et al.,
2011; Tan et al., 2008). It is indicated that CRP has also inﬂu-
ence on atherosclerotic process via damage of endothelial cells,
and formation, maturation, and ﬁnal disruption of atheroma-
tous plaque. Studies of Lai et al. designed to evaluate the rela-
tionship between the characteristics of coronary
atherosclerotic plaques and inﬂammatory biomarkers, indi-
cated that mean concentrations of high-sensitivity CRP (hs-
CRP) and IL-6 were signiﬁcantly higher in the three plaque
groups in comparison to controls (Lai et al., 2011). Their ﬁnd-
ings support our results, which may indicate that inﬂammation
is engaged in the occurrence and development of plaque in
ACS. Moreover, ﬁndings of Lai et al. suggested that both
hs-CRP as well as IL-6 concentrations may be recognized as
one of the indexes to evaluate the degree of coronary heart dis-
ease (Lai et al., 2011). Interestingly our ﬁndings indicated that
the highest percentage of negative results (speciﬁcity) revealedand angiographic extent of the coronary artery disease in the total
ease 2-vessels disease
N= 24
3-vessels disease
N= 19
P-value
10.20) 8.75 (6.60–11.00) 7.70 (6.50–10.10) NS
) 4.4 (1.3–5.7) 3.8 (0.9–4.7) 0.0419
8.9) 18.0 (9.1–32.8) 10.4 (3.8–14.7) NS
48) 222 (190–254 208 (176–216) NS
11.3) 10.8 (10.0–11.3) 10.5 (9.3–11.2) NS
33.8) 30.4 (24.9–34.5) 29.4 (24.5–35.1) NS
) 75 (61–105) 55 (41–67) NS
C-reactive protein, IL-6 – interleukin-6, PLT – platelet count, MPV –
n.
.0.
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Table 7 Diagnostic usefulness of inﬂammation and platelet biomarkers in the total study group of ACS patients.
Cut-oﬀ AUC SE Sensitivity [%] Speciﬁcity [%] PPV [%] NPV [%] ACC [%]
WBC[x103/lL] 4.7 0.787 0.043 98 13 78 67 77
CRP [mg/L] 0.4 0.798 0.040 96 20 79 60 77
IL-6 [pg/mL] 9.1 0.707 0.052 67 90 94 55 76
MPV [fL] 9.6 0.904 0.026 93 57 87 71 84
b-TG [IU/mL] 36.3 0.961 0.016 89 93 90 97 90
ACS – acute coronary syndrome, WBC – white blood cells count, CRP – C-reactive protein, IL-6 – interleukin-6, PLT – platelet count, MPV –
mean platelet volume, L-PLT – large platelet, b-TG – b-thromboglobulin, AUC – area under the ROC curve, SE – Standard Error, PPV –
positive predictive value, NPV – negative predictive value, ACC – diagnostic accuracy.
Conversion factors to SI units are as follows: for WBC – 1.0, for PLT – 1.0.
The utility of inﬂammation and platelet biomarkers in patients with acute coronary syndromes 7IL-6. The AUCs for all inﬂammation parameters tested were
similar, however the highest AUCs showed WBC and CRP.
Literature data regarding the evaluation of CRP and IL-6
concentrations depending on the sensitivity of signs and symp-
toms as compared to control individuals are limited. Tan et al.
indicated higher IL-6 concentrations in patients with STEMI
compared with controls (Tan et al., 2008), which is in agree-
ment with our ﬁndings. Zhang et al. reported increased con-
centrations of CRP and IL-6 in NSTEMI patients in
comparison to stable angina pectoris subjects and healthy indi-
viduals (Zhang et al., 2007), which is also in line with our
research. In the current study signiﬁcant differences for IL-6
were not found only between UA vs. controls. These results
may indicate that IL-6 can be recognized as an inﬂammatory
biomarker to identify individuals at high risk of myocardial
infarction.
The analysis of differences between the ACS subgroups
showed that statistically signiﬁcant variations were found
between STEMI vs. UA subgroup for CRP and between
STEMI vs. UA subgroup as well as between NSTEMI vs.
UA subgroup for IL-6 concentrations. Moreover, our study
showed that CRP revealed a trend toward to be lower in
NSTEMI patients as compared to STEMI subjects, while IL-
6 showed inverse tendency; however these differences were
not signiﬁcant (Table 4). These observations are in opposite
to results obtained by Di Stefano et al. and Habib et al., which
indicated differences between STEMI vs. NSTEMI concerning
CRP and IL-6 (Habib et al., 2011). Additionally Di Stefano
and colleagues revealed higher median value of WBC in
STEMI subjects as compared to NSTEMI (Di Stefano et al.,
2009). These ﬁndings altogether suggest a differential inﬂam-
matory pattern regarding CRP and IL-6 in ACS patients
depending on the severity of signs and symptoms of CAD.
However further studies are needed to elucidate this aspect.
In the study group of patients with ACS except for CRP
concentrations we did not reveal signiﬁcant differences
between the advancement of coronary artery changes and
inﬂammation as well as platelet parameters. Statistically lower
CRP concentrations were found in the group of ACS patients
with 1-vessel coronary artery disease as compared to subjects
with 2-vessel coronary artery disease. Studies of other authors
revealed a correlation between lower ﬁbrous cap thickness with
elevated inﬂammation biomarkers and accumulation of
inﬂammatory cells within atherosclerotic plaque (Raffel
et al., 2007). It is hypothesized that increased inﬂammation
conduct to increased platelet activation in ACS subjects and
thus to the formation of atherosclerotic plaque (Ueba et al.,
2014; Williams et al., 2014).Please cite this article in press as: Kamin´ska, J. et al., The utility of inflammation and
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development of atherosclerotic plaque and thrombus forma-
tion after coronary plaque destabilization (Pal et al., 2014;
Zhang et al., 2007). The rupture of an unstable plaque con-
tributes to the local thrombin generation and ﬁbrin deposition,
which lead to the platelet activation, adhesion and aggrega-
tion, and thus the formation of intra-coronary thrombus
(Parguin˜a et al., 2010). It is reported that individuals with
CAD have circulating activated platelets, platelet-derived
microparticles, monocyte-platelet aggregates, and increased
reactivity of the platelet (Brambilla et al., 2008; Zhang et al.,
2007). Activated platelets and platelet-leukocyte aggregates
were found to be statistically elevated in subjects with unstable
angina as compared to patients with stable angina (Brambilla
et al., 2008).
Our studies showed that among chosen platelet morpholog-
ical parameters only statistically increased median MPV in the
total group of ACS patients as compared to controls was
found. Current study did not reveal signiﬁcant differences con-
cerning PLT, which is in line with results of other researchers
(Bychowski, 2002; Mathur et al., 2001; Turk et al., 2013).
Interestingly, increased MPV was indicated as a predictor of
death in ACS patients, but the cut-off point of MPV related
to poor prognosis has not been settled (Maden et al., 2009;
Slavka et al., 2011). However studies of Klovaite et al. indi-
cated that subjects with MPV< 7.4 fL vs. >7.4 fL had
increased risk of myocardial infarction (Klovaite et al.,
2011). Platelet size reﬂects platelet function (Sharpe and
Trinick, 1993). Larger platelets are more reactive, contributing
to the formation of free arachidonic acid, which can be con-
verted into prostaglandins (e.g. thromboxane A2 – the most
potent platelet-aggregating factor) and leukotrienes (which
are able to enhance the inﬂammatory response) (Pal et al.,
2014; Sharpe and Trinick, 1993). Larger and more active pla-
telets may accelerate the formation and extension of intracoro-
nary thrombus, which lead to the acute thrombotic events in
ACS subjects (Pal et al., 2014). In the whole group of ACS
patients current study showed very strong positive correlation
between MPV and LPLT (which are platelets with MPV > 12
fL) (data not present). Similar correlations were also found in
the study group depending on the severity of signs and symp-
toms (data not present). Martin et al. indicated that in myocar-
dial infarction cases large platelet size was recognized as an
independent risk factor and may be a predictive parameter
of recurrent myocardial infarction (Martin et al., 1991).
Kilic¸li-Camur et al. found increased MPV in patients with
myocardial infarction in comparison to subjects with stable
angina and healthy individuals (Kilic¸li-Camur et al., 2005).platelet biomarkers in patients with acute coronary syndromes. Saudi Journal of
8 J. Kamin´ska et al.Also ﬁndings of Pal et al. indicated higher MPV in ACS
patients than in healthy individuals (Pal et al., 2014). Likewise
our results are able to support the hypothesis that increased
MPV may be a potentially useful predictive biomarker in
CAD. Moreover, analyzing MPV depending on the sensitivity
of signs and symptoms as compared to control group, studies
revealed that statistically signiﬁcant differences were also
found. Yilmaz et al. indicated that elevated MPV in NSTEMI
determined both an increased risk of myocardial infarction as
well as ischemic complications (Yilmaz et al., 2008). These
data may indicate that platelet activation can play a signiﬁcant
role in the pathogenesis and clinical outcome of ACS, and thus
might reﬂect the plaque instability and accompanying inﬂam-
mation and vascular thrombosis (Zhang et al., 2007).
Activated platelets realize from a-granules markers of their
activation, such as b-TG and soluble form of P-selectin (sP-
selectin) (Kaplan and Owen, 1981; Michelson et al., 2001).
In the total group of ACS patients median b-TG activity
was signiﬁcantly higher as compared to controls. Analyzing
the b-TG activity depending on the sensitivity of signs and
symptoms as compared to control group studies revealed that
likewise differences were found. b-TG also revealed the best
diagnostic usefulness among all parameters tested in the study.
It should be emphasized that investigations evaluating the b-
TG in STEMI, NSTEMI, and UA subjects are very limited
and imprecise. The evaluation of b-TG, however regarding
the concentration of protein tested, so far has been conducted
only by Smitherman et al. (1981). According to authors the b-
TG levels obtained in subjects with acute myocardial infarc-
tion were increased in general within the ﬁrst 3–4 days of hos-
pitalization (Smitherman et al., 1981). Current study indicated
that the evaluation of b-TG activity may be a suitable param-
eter to grade the platelet activity in ACS patients. It should be
emphasized, that in the available literature there are no data
regarding the evaluation of b-TG activity in ACS, therefore
the discussion concerning this aspect is unsatisfactory. How-
ever studies of Zhang et al. revealed that sP-selectin, which is
also recognized as biomarker of platelet activation in vivo,
was increased in NSTEMI and UA subjects as compared to
controls (Zhang et al., 2007).
5. Study limitations
Current study was designed to evaluate the diagnostic value of
chosen inﬂammation and platelet activation parameters in
ACS patients depending on the severity of signs and symp-
toms. However, the study had some limitations. Firstly, small
number of subjects included in the study could cause a selec-
tion bias. Hence, such studies should be performed on a larger
study group. Secondly, it would be also valuable to perform
the analysis of above-mentioned parameters in patients with
stable angina and compare these ﬁndings with results obtained
in ACS (similar study is in progress).
6. Conclusion
Our study revealed that WBC, CRP, and IL-6 as an inﬂamma-
tion parameters and MPV and b-TG as platelet biomarkers
may be useful indicators of the presence of CAD. The AUCs
for all above-mentioned parameters were signiﬁcantly higher
than AUC= 0.500, which may indicate their potential clinicalPlease cite this article in press as: Kamin´ska, J. et al., The utility of inflammation and
Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.10.015signiﬁcance in ACS. Additionally current ﬁndings indicated a
different inﬂammatory pattern regarding CRP and IL-6 con-
centrations in ACS patients depending on the severity of signs
and symptoms; however further studies are needed to elucidate
this aspect.
Author Contributions
JK: concept and design of the study, statistical analysis and
interpretation of data, drafting the article, ﬁnal approval of
the submitted version of article.
OMK: the concept and design of the study, statistical anal-
ysis and interpretation of data, drafting the article, ﬁnal
approval of the submitted version of article.
ESC: acquisition of data, revising article critically, ﬁnal
approval of the submitted version of article.
JMK: analysis and interpretation of data, revising article
critically, ﬁnal approval of the submitted version of article.
JB: analysis and interpretation of data, revising article crit-
ically, ﬁnal approval of the submitted version of article.
HK: the concept and design of the study, revising article
critically, ﬁnal approval of the submitted version of article.
Disclosures
The authors declare no conﬂict of interests.
References
Arbab-Zadeh, A., Nakano, M., Virmani, R., et al, 2012. Acute
coronary events. Circulation 125 (9), 1147–1156.
Borsey, D.Q., Dawes, J., Fraser, D.M., et al, 1980. Plasma beta-
thromboglobulin in diabetes mellitus. Diabetologia 18 (5), 353–357.
Brambilla, M., Camera, M., Colnago, D., et al, 2008. Tissue factor in
patients with acute coronary syndromes: expression in platelets,
leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb
Vasc. Biol. 28 (5), 947–953.
Bychowski, J., 2002. Ocena wybranych parametro´w aktywacji płytek
krwi u chorych z niestabilnaz dławicaz piersiowaz. Doctoral Thesis.
Białystok.
Di Stefano, R., Di Bello, V., Barsotti, M.C., et al, 2009. Inﬂammatory
markers and cardiac function in acute coronary syndrome: differ-
ence in ST-segment elevation myocardial infarction (STEMI) and
in non-STEMI models. Biomed. Pharmacother. 63 (10), 773–780.
Gilardi, E., Iacomani, P., Marsiliani, D., et al, 2014. Biomarkers in the
prediction and management of acute coronary syndromes: current
perspectives. Res. Rep. Clin. Cardiol. 5, 21–31.
Go, A.S., Mozaffarian, D., Roger, V.L., et al, 2014. American heart
association statistics committee and stroke statistics subcommittee.
Heart disease and stroke statistics-2013 Update: a report from the
American Heart Association. Circulation 129 (3), e28–e292.
Habib, S.S., Kurdi, M.I., Aseri, Z.A., et al, 2011. CRP levels are higher
in patients with ST elevation than non-ST elevation acute coronary
syndrome. Arq. Bras. Cardiol. 96 (1), 13–17.
Hansson, G.K., 2005. Inﬂammation, atherosclerosis, and coronary
artery disease. N Engl. J. Med. 352 (16), 1685–1695.
Heeschen, C., Dimmeler, S., Hamm, C.W., et al, 2003. CAPTURE
Study Investigators. Soluble CD40 ligand in acute coronary
syndromes. N. Engl. J. Med. 348 (12), 1104–1111.
Heeschen, C., Dimmeler, S., Hamm, C.W., et al, 2005. CAPTURE
Study Investigators. Pregnancy-associated plasma protein-A levels
in patients with acute coronary syndromes: comparison with
markers of systemic inﬂammation, platelet activation, and myocar-
dial necrosis. J. Am. Coll. Cardiol. 45 (2), 229–237.platelet biomarkers in patients with acute coronary syndromes. Saudi Journal of
The utility of inﬂammation and platelet biomarkers in patients with acute coronary syndromes 9Hristov, M., Weber, C., 2015. Myocardial infarction and inﬂamma-
tion: lost in the biomarker labyrinth. Circ. Res. 116 (5), 781–783.
Kaplan, K.L., Owen, J., 1981. Plasma levels of beta-thromboglobulin
and platelet factor 4 as indices of platelet activation in vivo. Blood
57 (2), 199–202.
Kilic¸li-Camur, N., Demirtunc¸, R., Konuralp, C., et al, 2005. Could
mean platelet volume be a predictive marker for acute myocardial
infarction? Med. Sci. Monit. 11 (8). CR387-392.
Klovaite, J., Benn, M., Yazdanyar, S., et al, 2011. High platelet
volume and increased risk of myocardial infarction: 39,531
participants from the general population. J. Thromb. Haemost. 9
(1), 49–56.
Lai, C., Ji, Y., Liu, X., et al, 2011. Relationship between coronary
atherosclerosis plaque characteristics and high sensitivity C-reac-
tive proteins, interleukin-6. Chin. Med. J. 124 (16), 2452–2456.
Lindahl, B., Toss, H., Siegbahn, A., et al, 2000. Markers of myocardial
damage and inﬂammation in relation to long-term mortality in
unstable coronary artery disease. FRISC Study Group. Fragmin
during Instability in Coronary Artery Disease. N. Engl. J. Med. 343
(16), 1139–1147.
Maden, O., Kacmaz, F., Selcuk, H., et al, 2009. Relationship of
admission hematological indexes with myocardial reperfusion
abnormalities in acute ST segment elevation myocardial infarction
patients treated with primary percutaneous coronary interventions.
Can. J. Cardiol. 25 (6), e164–e168.
Martin, J.F., Bath, P.M., Burr, M.L., 1991. Inﬂuence of platelet size
on outcome after myocardial infarction. Lancet 338 (8780), 1409–
1411.
Mathur, A., Robinson, M.S., Cotton, J., et al, 2001. Platelet reactivity
in acute coronary syndromes: evidence for differences in platelet
behaviour between unstable angina and myocardial infarction.
Thromb. Haemost. 85 (6), 989–994.
Michelson, A.D., Barnard, M.R., Krueger, L.A., et al, 2001. Circu-
lating monocyte-platelet aggregates are a more sensitive marker of
in vivo platelet activation than platelet surface P-selectin: studies in
baboons, human coronary intervention, and human acute myocar-
dial infarction. Circulation 104 (13), 1533–1537.
Nording, H.M., Seizer, P., Langer, H.F., 2015. Platelets in inﬂamma-
tion and atherogenesis. Front. Immunol. 6, 98.
Pal, R., Bagarhatta, R., Gulati, S., et al, 2014. Mean platelet volume in
patients with acute coronary syndromes: a supportive diagnostic
predictor. J Clin Diagn Res. 8 (8). MC01-4.
Parguin˜a, A.F., Grigorian-Shamajian, L., Agra, R.M., et al, 2010.
Proteins involved in platelet signaling are differentially regulated in
acute coronary syndrome: a proteomic study. PLoS ONE 5 (10),
e13404.
Raffel, O.C., Tearney, G.J., Gauthier, D.D., et al, 2007. Relationship
between a systemic inﬂammatory marker, plaque inﬂammation,Please cite this article in press as: Kamin´ska, J. et al., The utility of inflammation and
Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.10.015and plaque characteristics determined by intravascular optical
coherence tomography. Arterioscler Thromb. Vasc. Biol. 27 (8),
1820–1827.
Sharpe, P.C., Trinick, T., 1993. Mean platelet volume in diabetes
mellitus. Q. J. Med. 86 (11), 739–742.
Slavka, G., Perkmann, T., Haslacher, H., et al, 2011. Mean platelet
volume may represent a predictive parameter for overall vascular
mortality and ischemic heart disease. Arterioscler Thromb. Vasc.
Biol. 31 (5), 1215–1218.
Smitherman, T.C., Milam, M., Woo, J., et al, 1981. Elevated beta
thromboglobulin in peripheral venous blood of patients with acute
myocardial ischemia: direct evidence for enhanced platelet reactiv-
ity in vivo. Am. J. Cardiol. 48 (3), 395–402.
Spinas, E., Kritas, S.K., Saggini, A., et al, 2014. Role of mast cells in
atherosclerosis: a classical inﬂammatory disease. Int. J. Immuno-
pathol. Pharmacol. 27 (4), 517–521.
Sukhija, R., Fahdi, I., Garza, L., et al, 2007. Inﬂammatory markers,
angiographic severity of coronary artery disease, and patient
outcome. Am. J. Cardiol. 99 (7), 879–884.
Tan, J., Hua, Q., Gao, J., et al, 2008. Clinical implications of elevated
serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and
tissue inhibitor of metalloproteinase-1 in patients with acute ST-
segment elevation myocardial infarction. Clin. Cardiol. 31 (9), 413–
418.
Tanindi, A., Sahinarslan, A., Elbeg, S., et al, 2011. Relationship
between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical
presentation, extent and severity of atherosclerotic coronary artery
disease. Open. Cardiovasc. Med. J. 5, 110–116.
Turk, U., Tengiz, I., Ozpelit, E., et al, 2013. The relationship between
platelet indices and clinical features of coronary artery disease.
Kardiol. Pol. 71 (11), 1129–1134.
Ueba, T., Nomura, S., Inami, N., et al, 2014. Elevated RANTES level
is associated with metabolic syndrome and correlated with
activated platelets associated markers in healthy younger men.
Clin. Appl. Thromb. Hemost. 20 (8), 813–818.
Wang, X.H., Liu, S.Q., Wang, Y.L., et al, 2014. Correlation of serum
high-sensitivity C-reactive protein and interleukin-6 in patients with
acute coronary syndrome. Genet. Mol. Res. 13 (2), 4260–4266.
Williams, M.S., Rogers, H.L., Wang, N.Y., et al, 2014. Do platelet-
derived microparticles play a role in depression, inﬂammation, and
acute coronary syndrome? Psychosomatics 55 (3), 252–260.
Yilmaz, M.B., Cihan, G., Guray, Y., et al, 2008. Role of mean platelet
volume in triagging acute coronary syndromes. J. Thromb.
Thrombolysis. 26 (1), 49–54.
Zhang, S.Z., Jin, Y.P., Qin, G.M., et al, 2007. Association of platelet-
monocyte aggregates with platelet activation, systemic inﬂamma-
tion, and myocardial injury in patients with non-st elevation acute
coronary syndromes. Clin. Cardiol. 30 (1), 26–31.platelet biomarkers in patients with acute coronary syndromes. Saudi Journal of
